Downregulating carnitine palmitoyl transferase 1 affects disease progression in the SOD1 G93A mouse model of ALS

Area of Science:

• Neuroscience
• Metabolic Research
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by motor neuron death.
• The underlying causes and mechanisms of ALS remain largely unknown.
• Metabolic dysfunction is increasingly implicated in neurodegenerative diseases.

Purpose of the Study:

• To investigate the role of lipid metabolism, particularly carnitine palmitoyl transferase 1 (CPT1), in the SOD1 G93A mouse model of ALS.
• To determine if modulating CPT1 activity impacts ALS disease progression and associated pathologies.

Main Methods:

• Utilized the SOD1 G93A mouse model, a common model for studying ALS.
• Employed pharmacological and genetic methods to downregulate CPT1 activity.
• Administered high-fat diets and corticosterone to upregulate CPT1 activity.
• Assessed disease symptoms, inflammation, oxidative stress, mitochondrial function, and gut microbiota composition.

Main Results:

• Dysregulated CPT1 lipid metabolism correlated with ALS disease progression in SOD1 G93A mice.
• Pharmacological and genetic downregulation of CPT1 ameliorated ALS symptoms, reduced inflammation and oxidative stress, and improved mitochondrial function.
• Upregulation of CPT1 activity via high-fat diet or corticosterone exacerbated disease progression.
• Downregulating CPT1 shifted the gut microbiota towards a protective phenotype.

Conclusions:

• CPT1-mediated lipid metabolism plays a critical role in the pathogenesis of ALS in the SOD1 G93A mouse model.
• Modulating CPT1 activity represents a potential therapeutic strategy for ALS.
• Targeting CPT1 may influence the gut microbiome, contributing to therapeutic benefits in ALS.